
CLAIMS

1. Use of a compound of formula (I)



(I)

or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a hydrate or solvate of a salt thereof, in the preparation of a medicament for the treatment of advanced or metastatic cancer with at least one mutation in a homologous recombination gene.

2. Use according to Claim 1, in which the cancer is selected form the group consisting of ovarian cancer, fallopian tube cancer, primary peritoneal cancer, breast cancer, castration resistant prostate cancer, and pancreatic ductal adenocarcinoma.

3. Use according to Claim 1, in which the cancer is selected form the group consisting of metastatic ovarian cancer, metastatic fallopian tube cancer, metastatic primary peritoneal cancer, metastatic breast cancer, metastatic castration resistant prostate cancer, and metastatic pancreatic ductal adenocarcinoma.

4. Use according to Claim 1, 2 or 3, in which the compound is for use as monotherapy.

5. Use according to any preceding claim, in which the at least one mutation in a homologous recombination gene is a mutation, deletion or insertion in one or more DNA repair genes selected form the group consisting of ARID1A, ATM, ATRX, BAP1, BLM, BRCA1, BRCA2, BARD1, BRIP1, CHEK1, CHEK2, FANCA/C/D2/E/F/G/L, MRE11A, NBN, PALB2, RAD50, RAD51C, RAD51D, RAD51, RAD51B and/or WRN.

6. Use according to any preceding claim, in which the at least one mutation in a homologous recombination gene is a mutation, deletion or insertion in BRCA1 and/or BRCA2.

7. Use of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a hydrate or solvate of a salt thereof, and a pharmaceutically suitable carrier, in the preparation of a medicament for the treatment of advanced or metastatic cancer with at least one mutation in a homologous recombination gene.

8. Use according to Claim 7, in which the cancer is selected form the group consisting of ovarian cancer, fallopian tube cancer, primary peritoneal cancer, breast cancer, castration resistant prostate cancer, and pancreatic ductal adenocarcinoma.

9. Use according to Claim 7, in which the cancer is selected form the group consisting of metastatic ovarian cancer, metastatic fallopian tube cancer, metastatic primary peritoneal cancer, metastatic breast cancer, metastatic castration resistant prostate cancer, and metastatic pancreatic ductal adenocarcinoma.

10. Use according to Claim 7, 8 or 9, in which the compound is for use as monotherapy.

11. Use according to any of Claims 7 to 10, in which the at least one mutation in a homologous recombination gene is a mutation, deletion or insertion in one or more DNA repair genes selected form the group consisting of ARID1A, ATM, ATRX, BAP1, BLM, BRCA1, BRCA2, BARD1, BRIP1, CHEK1, CHEK2, FANCA/C/D2/E/F/G/L, MRE11A, NBN, PALB2, RAD50, RAD51C, RAD51D, RAD51, RAD51B and/or WRN.

12. Use according to any of Claims 7 to 11, in which the at least one mutation in a homologous recombination gene is a mutation, deletion or insertion in BRCA1 and/or BRCA2.